Balancing Innovation: India’s Views for Pharmaceuticals in the Efta Trade Deal
IIPRD
APRIL 2, 2024
The implementation of TRIPS-Plus provisions can also readily facilitate the emergence of monopoly power for brand-name pharmaceutical companies. [v] xii] This clause gives the original researchers ownership of their clinical trial data for a predetermined amount of time, usually ranging for a period of six years. 6, 2024). [ii]
Let's personalize your content